Wed, Apr 16, 2014, 1:31 PM EDT - U.S. Markets close in 2 hrs 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Cardiome Pharma Corp. Message Board

  • downtrendbuyer downtrendbuyer May 15, 2013 5:07 PM Flag

    Shorties, crooks, manipulation...

    Eventually this stock will rally up...! Now it's just waiting and adding more when those crooks try to scare us longs... There should be no reasonable reason for these kinds of drops if we look at Q1 summary... Manipulation-- just saying ;O))!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think the reason is the lack of good news in the CEO update. I think his tone was very wishful and uncertain a out prospects. The investment community has lost interest completely in cardiome for reasons that are obvious and also for reasons that are not obvious to us commoners. Not a single question was asked after the cc. My expectations after this cc was that crme will trade sideways or drop until we have a truly significant update. I am not sure to this day why Merck lost faith in this molecule? And why the previous chairman quit? And why on earth were they recruiting patients for ACT 5 in Peru where the safety mishap occurred leading to the halt. The revival of Vernakalant as Hunter hopes to happen is a long long shot. I am a believer in the molecule and have paid dearly for my faith in it. I am beginning to have more doubts about prospects here though and the cc did not alleviate them but rather exacerbate my doubts. I am keeping my 20 k shares for now and hoping and praying for a miracle and that whatever the company and Merck and the FDA Know that we don't know is not a as bad a it seems.

      Sentiment: Hold

 
CRME
7.01+0.19(+2.79%)1:28 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.